Mumbai: A leading Indian pharmaceutical company focused on addressing critical unmet medical needs, BDR Pharmaceuticals International Pvt. Ltd. today announced the launch of XATRONEM-AV (Aztreonam + Avibactam Injection) 2 g, an advanced antibacterial therapy. This drug is developed for the treatment of serious infections caused by multidrug-resistant (MDR) gram-negative bacteria.(Photo Courtesy – AI)

Are you using your mobile phone when you wake up? So beware… These morning habits increase the risk of heart attack

The launch comes at a time when antimicrobial resistance (AMR) is emerging as one of the most pressing health challenges facing the world. Drug-resistant infections directly cause about 1.9 million deaths each year, while they are thought to be associated with more than 8.2 million deaths worldwide. According to a study published in The Lancet, AMR could cause about 3.9 million deaths between 2025 and 2050. In addition, healthcare costs and lost productivity are likely to create an economic burden of about US$1 trillion annually.

This treatment will be used for patients suffering from serious infections and hospitalized. These include complicated abdominal infections, hospital-acquired infections, bloodstream infections, ventilator-associated infections, and other serious Gram-negative bacterial infections that fail conventional treatment.

The launch of XATRONEM-AV is a step forward in BDR Pharma’s tradition of innovation. The company has a tradition of successful introduction of several first generic drugs in India such as Caspofungin, Anidulafungin and Biapenem along with its leading brands Xavitaz, Zisavel and Dalbonova. The company stands firm in its commitment to provide quality treatment to critical patients across the country.

XATRONEM-AV, available as a 2 g injection, makes advanced antimicrobial therapy easier for patients fighting life-threatening infections. This drug will help in timely and effective treatment of multidrug-resistant gram-negative infections. The growing problem of antimicrobial resistance has significantly increased the complexity and cost of patient care worldwide. Infections caused by carbapenem-resistant and multidrug-resistant gram-negative bacteria prolong hospital stays, add to healthcare costs, increase mortality, and limit treatment options. Increased availability of advanced therapies enables healthcare professionals to make timely and accurate treatment decisions, which can improve patient health outcomes.

Commenting on the launch, Dharmesh Shah, Chairman, BDR Pharma said, “Antimicrobial resistance is one of the most pressing healthcare challenges of our time. It is putting a huge strain on both patients and the healthcare system. With the launch of XATRONEM-AV, we aim to provide healthcare professionals with an important treatment option against multidrug-resistant Gram-negative infections. Also, BDR Pharma’s commitment to bringing innovative and accessible treatments to patients in need It will also strengthen the commitment.”

BDR Pharmaceuticals International Pvt. Ltd. About Established in 2003, BDR Pharmaceuticals International Pvt. Ltd. It has steadily grown domestically and internationally over the past two decades to become a trusted name in the pharmaceutical industry. The company has specialized in pharmaceutical API production and manufacturing of advanced formulations.

Reliance Foundation Hospital : New life for 6 patients in one day; A proud record of Reliance Foundation Hospital

The BDR group mainly consists of BDR Pharmaceuticals International Pvt. Ltd. and BDR Life Sciences Pvt. Ltd. These two companies include and have carved their own niche in the API and formulation manufacturing space. BDR Group’s main focus is on the development of five specialty treatment areas: Oncology, Critical Care, Gynaecology, Chronic Cluster and Neurology.